Medicare Part D GLP-1 Coverage Rules in 2026
A 68-year-old Medicare Part D enrollee with a BMI of 34, hypertension, and no diabetes diagnosis takes her semaglutide (Wegovy) prescription to the pharmacy and is quoted a cash price near $1,000…
The regulatory and access context around GLP-1 and GLP-3 therapies — FDA status, shortage and compounding policy, and how supply changes affect availability. Informational coverage, not legal or medical guidance.
A 68-year-old Medicare Part D enrollee with a BMI of 34, hypertension, and no diabetes diagnosis takes her semaglutide (Wegovy) prescription to the pharmacy and is quoted a cash price near $1,000…
A medical spa running forty semaglutide patients a week out of a strip-mall suite in Scottsdale got a call from its 503B supplier in March 2025: bulk semaglutide vials were being discontinued…
The Shortage Is Over — But the Access Problem Isn't In February 2025, the FDA officially removed semaglutide from its drug shortage database. On paper, that sounds like a win. In practice…